Oruka Therapeutics (ORKA) Gains from Sales and Divestitures (2014 - 2026)
Oruka Therapeutics (ORKA) recorded quarterly Gains from Sales and Divestitures of $125719.0 in Q1 2026, down 87.55% quarter-over-quarter from $1.0 million in Q4 2025, and down 78.2% on a YoY basis from $576571.0 in Q1 2025.
Oruka Therapeutics (ORKA) Gains from Sales and Divestitures (2014 - 2026) Analysis & Trends
Oruka Therapeutics' Gains from Sales and Divestitures history runs 9 years deep, the most recent figure standing at $125719.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures fell 78.2% year-over-year to $125719.0; the TTM figure through Mar 2026 stood at $125719.0 (down 78.2% YoY), while the FY2025 annual figure was $1.0 million, changed N/A from the prior year.
- Gains from Sales and Divestitures was $125719.0 for Q1 2026 at Oruka Therapeutics, down from $1.0 million in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $3.1 million in Q3 2024 to a low of $91000.0 in Q4 2023.
- Historically, Gains from Sales and Divestitures has averaged $835450.7 across 4 years, with a median of $576571.0 in 2025.
- The sharpest annual moves came in 2025 and 2026: Gains from Sales and Divestitures slumped 72.09% in 2025, then slumped 78.2% in 2026.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $91000.0 in 2023, then soared by 3256.44% to $3.1 million in 2024, then slumped by 66.93% to $1.0 million in 2025, then sank by 87.55% to $125719.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $125719.0 (Q1 2026), $1.0 million (Q4 2025), and $852515.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Oruka Therapeutics | 3.86 Bn | 3.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125,719.00 |
| Mar 31, 2026 | 125,719.00 |
| Dec 31, 2025 | 1.01 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 852,515.00 |
| Sep 30, 2025 | 852,515.00 |
| Jun 30, 2025 | 137,972.00 |
| Jun 30, 2025 | 137,972.00 |
| Mar 31, 2025 | 576,571.00 |
| Mar 31, 2025 | 576,571.00 |
| Sep 30, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Dec 31, 2023 | 91,000.00 |
| Dec 31, 2023 | 91,000.00 |
| Dec 31, 2018 | 842.00 |
| Dec 31, 2018 | 842.00 |
| Sep 30, 2018 | 14,935.00 |
| Sep 30, 2018 | 14,935.00 |
| Jun 30, 2018 | 14,935.00 |
| Jun 30, 2018 | 14,935.00 |